Yuan-Kai Shi (Yuankai Shi)

Publication Activity (10 Years)

Years Active: 2017-2024
Publications (10 Years): 46

Top Topics

Tyrosine Kinase

Cancer Stem Cells

Prognostic Factors

Top Venues

Asia-Pacific journal of clinical oncology

Cancer immunology, immunotherapy : CII

Thoracic cancer

This page only lists publications with an associated author ORCID identifier.

Publications

Ruyun Gao, Ning Lou, Lin Li, Tongji Xie, Puyuan Xing, Le Tang, Jiarui Yao, Xiaohong Han, Yuan-Kai Shi
Mutational variant allele frequency profile as a biomarker of response to immune checkpoint blockade in non-small cell lung Cancer. Journal of translational medicine 22 (1) (2024)
Ruyun Gao, Ning Lou, Lin Li, Tongji Xie, Puyuan Xing, Le Tang, Jiarui Yao, Xiaohong Han, Yuan-Kai Shi
Mutational variant allele frequency profile as a biomarker of response to immune checkpoint blockade in non-small cell lung Cancer. Journal of translational medicine 22 (1) (2024)
Qiaoyun Tan, Ruyun Gao, Xiaomei Zhang, Jianliang Yang, Puyuan Xing, Sheng Yang, Dan Wang, Guibing Wang, Shasha Wang, Jiarui Yao, Zhishang Zhang, Le Tang, Xiaobo Yu, Xiao-Hong Han, Yuan-Kai Shi
Longitudinal plasma proteomic analysis identifies biomarkers and combinational targets for anti-PD1-resistant cancer patients. Cancer immunology, immunotherapy : CII 73 (3) (2024)
Guangyu Fan, Tongji Xie, Lin Li, Le Tang, Xiaohong Han, Yuan-Kai Shi
Single-cell and spatial analyses revealed the co-location of cancer stem cells and SPP1+ macrophage in hypoxic region that determines the poor prognosis in hepatocellular carcinoma. NPJ precision oncology 8 (1) (2024)
Qiaoyun Tan, Ruyun Gao, Xiaomei Zhang, Jianliang Yang, Puyuan Xing, Sheng Yang, Dan Wang, Guibing Wang, Shasha Wang, Jiarui Yao, Zhishang Zhang, Le Tang, Xiaobo Yu, Xiao-Hong Han, Yuan-Kai Shi
Longitudinal plasma proteomic analysis identifies biomarkers and combinational targets for anti-PD1-resistant cancer patients. Cancer immunology, immunotherapy : CII 73 (3) (2024)
Qiaoyun Tan, Ruyun Gao, Xiaomei Zhang, Jianliang Yang, Puyuan Xing, Sheng Yang, Dan Wang, Guibing Wang, Shasha Wang, Jiarui Yao, Zhishang Zhang, Le Tang, Xiaobo Yu, Xiao-Hong Han, Yuan-Kai Shi
Longitudinal plasma proteomic analysis identifies biomarkers and combinational targets for anti-PD1-resistant cancer patients. Cancer immunology, immunotherapy : CII 73 (3) (2024)
Qiaoyun Tan, Ruyun Gao, Xiaomei Zhang, Jianliang Yang, Puyuan Xing, Sheng Yang, Dan Wang, Guibing Wang, Shasha Wang, Jiarui Yao, Zhishang Zhang, Le Tang, Xiaobo Yu, Xiao-Hong Han, Yuan-Kai Shi
Longitudinal plasma proteomic analysis identifies biomarkers and combinational targets for anti-PD1-resistant cancer patients. Cancer immunology, immunotherapy : CII 73 (3) (2024)
Guangyu Fan, Tongji Xie, Le Tang, Lin Li, Xiaohong Han, Yuan-Kai Shi
The co-location of CD14+APOE+ cells and MMP7+ tumour cells contributed to worse immunotherapy response in non-small cell lung cancer. Clinical and translational medicine 14 (9) (2024)
Guangyu Fan, Tongji Xie, Le Tang, Lin Li, Xiaohong Han, Yuan-Kai Shi
The co-location of CD14+APOE+ cells and MMP7+ tumour cells contributed to worse immunotherapy response in non-small cell lung cancer. Clinical and translational medicine 14 (9) (2024)
Guangyu Fan, Tongji Xie, Le Tang, Lin Li, Xiaohong Han, Yuan-Kai Shi
The co-location of CD14+APOE+ cells and MMP7+ tumour cells contributed to worse immunotherapy response in non-small cell lung cancer. Clinical and translational medicine 14 (9) (2024)
Guangyu Fan, Tongji Xie, Lin Li, Le Tang, Xiaohong Han, Yuan-Kai Shi
Single-cell and spatial analyses revealed the co-location of cancer stem cells and SPP1+ macrophage in hypoxic region that determines the poor prognosis in hepatocellular carcinoma. NPJ precision oncology 8 (1) (2024)
Qiaoyun Tan, Ruyun Gao, Xiaomei Zhang, Jianliang Yang, Puyuan Xing, Sheng Yang, Dan Wang, Guibing Wang, Shasha Wang, Jiarui Yao, Zhishang Zhang, Le Tang, Xiaobo Yu, Xiao-Hong Han, Yuan-Kai Shi
Longitudinal plasma proteomic analysis identifies biomarkers and combinational targets for anti-PD1-resistant cancer patients. Cancer immunology, immunotherapy : CII 73 (3) (2024)
Yuan-Kai Shi, Jianhua Chen, Helong Zhang, Zhihong Zhang, Yiping Zhang, Zhehai Wang, Shucai Zhang, Jian Zhao, Chunling Liu, Xiuwen Wang, Yanqiu Zhao, Changlu Hu, Lei Yang, Xuezhi Hao, Lin Wang, Yunpeng Liu, Yan Yu, Jun Zhao, Mengzhao Wang, Liangming Zhang, Sanyuan Sun, Yanping Hu, Kangsheng Gu, Xiaosheng Hang, Jinlu Shan, Yu Zhang, Bangxian Tan, Weihua Yang, Runxiang Yang, Meimei Si, Huaize Geng, Hui Li, Xiaoyan Kang
Efficacy and safety of iruplinalkib (WX-0593) in ALK-positive crizotinib-resistant advanced non-small cell lung cancer patients: a single-arm, multicenter phase II study (INTELLECT). BMC medicine 21 (1) (2023)
Yuan-Kai Shi, Jianhua Chen, Helong Zhang, Zhihong Zhang, Yiping Zhang, Zhehai Wang, Shucai Zhang, Jian Zhao, Chunling Liu, Xiuwen Wang, Yanqiu Zhao, Changlu Hu, Lei Yang, Xuezhi Hao, Lin Wang, Yunpeng Liu, Yan Yu, Jun Zhao, Mengzhao Wang, Liangming Zhang, Sanyuan Sun, Yanping Hu, Kangsheng Gu, Xiaosheng Hang, Jinlu Shan, Yu Zhang, Bangxian Tan, Weihua Yang, Runxiang Yang, Meimei Si, Huaize Geng, Hui Li, Xiaoyan Kang
Efficacy and safety of iruplinalkib (WX-0593) in ALK-positive crizotinib-resistant advanced non-small cell lung cancer patients: a single-arm, multicenter phase II study (INTELLECT). BMC medicine 21 (1) (2023)
Yuan-Kai Shi, Jianying Zhou, Yanqiu Zhao, Bo Zhu, Liangming Zhang, Xingya Li, Jian Fang, Jianhua Shi, Zhixiang Zhuang, Sheng Yang, Donglin Wang, Huiqing Yu, Longzhen Zhang, Rongsheng Zheng, Michael Greco, Tingting Wang
Results of the phase IIa study to evaluate the efficacy and safety of rezivertinib (BPI-7711) for the first-line treatment of locally advanced or metastatic/recurrent NSCLC patients with EGFR mutation from a phase I/IIa study. BMC medicine 21 (1) (2023)
Yan Qin, Xiaohui He, Xinrui Chen, Zu-Cheng Xie, Jianliang Yang, Sheng Yang, Peng Liu, Shengyu Zhou, Changgong Zhang, Lin Gui, Yuan-Kai Shi
Efficacy and safety of PD-1 monoclonal antibody plus rituximab in relapsed/refractory diffuse large B cell lymphoma patients. European journal of haematology (2023)
Yuan-Kai Shi, Jianying Zhou, Yanqiu Zhao, Bo Zhu, Liangming Zhang, Xingya Li, Jian Fang, Jianhua Shi, Zhixiang Zhuang, Sheng Yang, Donglin Wang, Huiqing Yu, Longzhen Zhang, Rongsheng Zheng, Michael Greco, Tingting Wang
Results of the phase IIa study to evaluate the efficacy and safety of rezivertinib (BPI-7711) for the first-line treatment of locally advanced or metastatic/recurrent NSCLC patients with EGFR mutation from a phase I/IIa study. BMC medicine 21 (1) (2023)
Yuan-Kai Shi, Jianhua Chen, Helong Zhang, Zhihong Zhang, Yiping Zhang, Zhehai Wang, Shucai Zhang, Jian Zhao, Chunling Liu, Xiuwen Wang, Yanqiu Zhao, Changlu Hu, Lei Yang, Xuezhi Hao, Lin Wang, Yunpeng Liu, Yan Yu, Jun Zhao, Mengzhao Wang, Liangming Zhang, Sanyuan Sun, Yanping Hu, Kangsheng Gu, Xiaosheng Hang, Jinlu Shan, Yu Zhang, Bangxian Tan, Weihua Yang, Runxiang Yang, Meimei Si, Huaize Geng, Hui Li, Xiaoyan Kang
Efficacy and safety of iruplinalkib (WX-0593) in ALK-positive crizotinib-resistant advanced non-small cell lung cancer patients: a single-arm, multicenter phase II study (INTELLECT). BMC medicine 21 (1) (2023)
Yuan-Kai Shi, Jianying Zhou, Yanqiu Zhao, Bo Zhu, Liangming Zhang, Xingya Li, Jian Fang, Jianhua Shi, Zhixiang Zhuang, Sheng Yang, Donglin Wang, Huiqing Yu, Longzhen Zhang, Rongsheng Zheng, Michael Greco, Tingting Wang
Results of the phase IIa study to evaluate the efficacy and safety of rezivertinib (BPI-7711) for the first-line treatment of locally advanced or metastatic/recurrent NSCLC patients with EGFR mutation from a phase I/IIa study. BMC medicine 21 (1) (2023)
Rongrong Luo, Pei Zhong, Xiying Li, Juan Cai, Yimin Tao, Bangzhu Xiong, Hancheng Zheng, Zhishang Zhang, Le Tang, Jiarui Yao, Yingrui Li, Yuan-Kai Shi, Xiao-Hong Han
High-throughput peptide arrays identify potential diagnostic autoantibody signatures in early-stage lung adenocarcinoma. Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology (2023)
Yuan-Kai Shi, Jianying Zhou, Yanqiu Zhao, Bo Zhu, Liangming Zhang, Xingya Li, Jian Fang, Jianhua Shi, Zhixiang Zhuang, Sheng Yang, Donglin Wang, Huiqing Yu, Longzhen Zhang, Rongsheng Zheng, Michael Greco, Tingting Wang
Results of the phase IIa study to evaluate the efficacy and safety of rezivertinib (BPI-7711) for the first-line treatment of locally advanced or metastatic/recurrent NSCLC patients with EGFR mutation from a phase I/IIa study. BMC medicine 21 (1) (2023)
Liling Huang, Le Tang, Liyuan Dai, Yuan-Kai Shi
The prognostic significance of tumor spread through air space in stage I lung adenocarcinoma. Thoracic cancer 13 (7) (2022)
Yunxia Tao, Yu Zhou, Le Tang, Haizhu Chen, Yu Feng, Yuan-Kai Shi
Toxicity profile of anaplastic lymphoma kinase tyrosine kinase inhibitors for patients with non-small cell lung cancer: A systematic review and meta-analysis. Investigational new drugs 40 (4) (2022)
Yunxia Tao, Yu Zhou, Haizhu Chen, Yan Qin, Xiaohui He, Peng Liu, Shengyu Zhou, Jianliang Yang, Liqiang Zhou, Changgong Zhang, Sheng Yang, Lin Gui, Yuan-Kai Shi
Prognostic role of red blood cell distribution width and platelet/lymphocyte ratio in early-stage classical Hodgkin lymphoma. Future oncology (London, England) 18 (15) (2022)
Haizhu Chen, Yunxia Tao, Yu Zhou, Peng Liu, Jianliang Yang, Xiaohui He, Shengyu Zhou, Yan Qin, Yongwen Song, Lin Gui, Changgong Zhang, Sheng Yang, Yuan-Kai Shi
The clinical features, treatment, and prognostic factors for peripheral T-cell lymphomas: A single-institution analysis of 240 Chinese patients. Asia-Pacific journal of clinical oncology (2022)
Yunxia Tao, Haizhu Chen, Yu Zhou, Xiaohu He, Yan Qin, Peng Liu, Shengyu Zhou, Jianliang Yang, Liqiang Zhou, Changgong Zhang, Sheng Yang, Lin Gui, Yuan-Kai Shi
A new prognostic model including platelet/lymphocyte ratio and International Prognostic Score 3 for freedom from progression in patients with previously untreated advanced classical Hodgkin lymphoma. Asia-Pacific journal of clinical oncology 18 (5) (2022)
Puyuan Xing, Qian Zhao, Li Zhang, Hanping Wang, Dingzhi Huang, Pei Hu, Yinghui Sun, Yuan-Kai Shi
Conteltinib (CT-707) in patients with advanced ALK-positive non-small cell lung cancer: a multicenter, open-label, first-in-human phase 1 study. BMC medicine 20 (1) (2022)
Haizhu Chen, Yan Qin, Jianliang Yang, Peng Liu, Xiaohui He, Shengyu Zhou, Changgong Zhang, Sheng Yang, Lin Gui, Yan Sun, Yuan-Kai Shi
Dismal outcome of relapsed or primary refractory adult T-cell lymphoblastic lymphoma: A retrospective study from China. Asia-Pacific journal of clinical oncology (2021)
Rongrong Luo, Cuiling Zheng, Wenya Song, Qiaoyun Tan, Yuan-Kai Shi, Xiao-Hong Han
High-throughput and multi-phases identification of autoantibodies in diagnosing early-stage breast cancer and subtypes. Cancer science (2021)
Yuan-Kai Shi, Jianqiu Wu, Zhen Wang, Liling Zhang, Zhao Wang, Mingzhi Zhang, Hong Cen, Zhigang Peng, Yufu Li, Lei Fan, Ye Guo, Liping Ma, Jie Cui, Yuhuan Gao, Haiyan Yang, Hongyu Zhang, Lin Wang, Weihua Zhang, Huilai Zhang, Liping Xie, Ming Jiang, Hui Zhou, Yuerong Shuang, Hang Su, Xiaoyan Ke, Chuan Jin, Xin Du, Xin Du, Li Liu, Yaming Xi, Zheng Ge, Ru Feng, Yang Zhang, Shengyu Zhou, Fan Xie, Qian Wang
Efficacy and safety of geptanolimab (GB226) for relapsed or refractory peripheral T cell lymphoma: an open-label phase 2 study (Gxplore-002). Journal of hematology & oncology 14 (1) (2021)
Yunxia Tao, Haizhu Chen, Yu Zhou, Yuan-Kai Shi
Meta-analysis of the prognostic and clinical value of serum 25-hydroxyvitamin D levels in previously untreated lymphoma. Future oncology (London, England) 17 (14) (2021)
Shasha Wang, Rongrong Luo, Yuan-Kai Shi, Xiaohong Han
The impact of the ALK fusion variant on clinical outcomes in EML4-ALK patients with NSCLC: a systematic review and meta-analysis. Future oncology (London, England) (2021)
Hao-Hua Zhu, Yu-Tao Liu, Yu Feng, Li-Na Zhang, Tong-Mei Zhang, Gui-Lan Dong, Pu-Yuan Xing, Hong-Yu Wang, Yuan-Kai Shi, Xing-Sheng Hu
Circulating tumor cells (CTCs)/circulating tumor endothelial cells (CTECs) and their subtypes in small cell lung cancer: Predictors for response and prognosis. Thoracic cancer 12 (20) (2021)
Yunxia Tao, Xiaohui He, Yan Qin, Peng Liu, Shengyu Zhou, Jianliang Yang, Liqiang Zhou, Changgong Zhang, Sheng Yang, Lin Gui, Yuan-Kai Shi
Low platelet/platelet distribution width and high platelet/lymphocyte ratio are adverse prognostic factors in patients with newly diagnosed advanced Hodgkin lymphoma. Leukemia & lymphoma 62 (13) (2021)
Ligang Xing, Yueyin Pan, Yuan-Kai Shi, Yongqian Shu, Jifeng Feng, Wei Li, Lejie Cao, Lifeng Wang, Wei Gu, Yong Song, Puyuan Xing, Yutao Liu, Wen Gao, Jiuwei Cui, Nana Hu, Rutian Li, Hua Bao, Yang Shao, Jinming Yu
Biomarkers of Osimertinib Response in Patients with Refractory, EGFR-T790M-positive Non-Small Cell Lung Cancer and Central Nervous System Metastases: The APOLLO Study. Clinical cancer research : an official journal of the American Association for Cancer Research 26 (23) (2020)
Liling Huang, Yuan-Kai Shi
Prognostic value of pretreatment smoking status for small cell lung cancer: A meta-analysis. Thoracic cancer 11 (11) (2020)
Fengyi Zhao, Yan Qin, Jianliang Yang, Peng Liu, Xiaohui He, Liqiang Zhou, Shengyu Zhou, Lin Gui, Haizeng Zhang, Xin Wang, Shiyu Jiang, Qiaofeng Zhong, Yu Zhou, Yuan-Kai Shi
R-CHOP immunochemotherapy plus surgery is associated with a superior prognosis in Chinese primary intestinal diffuse large B-cell lymphoma. Asia-Pacific journal of clinical oncology 16 (6) (2020)
Shiyu Jiang, Yan Qin, Lin Gui, Peng Liu, Hongxin Jiang, Biao Liu, Jianliang Yang, Sheng Yang, Xiaohui He, Shengyu Zhou, Xinhua Du, Yuting Yi, Jing Lin, Yuan-Kai Shi
Genomic Alterations and MYD88MUT Variant Mapping in Patients with Diffuse Large B-Cell Lymphoma and Response to Ibrutinib. Targeted oncology 15 (2) (2020)
Liling Huang, Shiyu Jiang, Yuan-Kai Shi
Tyrosine kinase inhibitors for solid tumors in the past 20 years (2001-2020). Journal of hematology & oncology 13 (1) (2020)
Shiyu Jiang, Yan Qin, Hongxin Jiang, Biao Liu, Jianming Shi, Fanlu Meng, Peng Liu, Jianliang Yang, Sheng Yang, Xiaohui He, Shengyu Zhou, Lin Gui, Hao Liu, Jing Lin, Han Han-Zhang, Yuan-Kai Shi
Molecular profiling of Chinese R-CHOP treated DLBCL patients: Identifying a high-risk subgroup. International journal of cancer 147 (9) (2020)
Yu Zhou, Yan Qin, Xiaohui He, Peng Liu, Jianliang Yang, Liqiang Zhou, Shengyu Zhou, Lin Gui, Sheng Yang, Changgong Zhang, Yuan-Kai Shi
Long-term survival and prognostic analysis of advanced stage follicular lymphoma in the rituximab era: A China single-center retrospective study. Asia-Pacific journal of clinical oncology 17 (3) (2020)
Yuan-Kai Shi, Qiqing Cai, Yu Jiang, Gang Huang, Minghong Bi, Baocheng Wang, Yuhong Zhou, Guowen Wang, Hongyan Ying, Zhiwei Tao, Qian Guo, Chao Gao
Activity and Safety of Geptanolimab (GB226) for Patients with Unresectable, Recurrent, or Metastatic Alveolar Soft Part Sarcoma: A Phase II, Single-arm Study. Clinical cancer research : an official journal of the American Association for Cancer Research 26 (24) (2020)
Shiyu Jiang, Yan Qin, Peng Liu, Jianliang Yang, Sheng Yang, Xiaohui He, Shengyu Zhou, Lin Gui, Changgong Zhang, Liqiang Zhou, Yan Sun, Yuan-Kai Shi
A prognostic nomogram constructed for relapsed or refractory diffuse large B-cell lymphoma patients. Asia-Pacific journal of clinical oncology (2019)
Shengyu Zhou, Lijie Zuo, Xiaohui He, Jinping Pi, Jun Jin, Yuan-Kai Shi
Efficacy and safety of rh-endostatin (Endostar) combined with pemetrexed/cisplatin followed by rh-endostatin plus pemetrexed maintenance in non-small cell lung cancer: A retrospective comparison with standard chemotherapy. Thoracic cancer 9 (11) (2018)
Yutao Liu, Xuezhi Hao, Xingsheng Hu, Junling Li, Yan Wang, Hongyu Wang, Puyuan Xing, Weihua Li, Jianming Ying, Xiaohong Han, Yuan-Kai Shi
Heterogeneity-based, multiple mechanisms in the resistance to osimertinib (AZD9291): A case report. Thoracic cancer 9 (4) (2018)
Jianping Xu, Xiaoyan Liu, Sheng Yang, Xiangru Zhang, Yuan-Kai Shi
Clinical response to apatinib monotherapy in advanced non-small cell lung cancer. Asia-Pacific journal of clinical oncology 14 (3) (2017)